Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-132876 · Präparat HOS-097310
Potential ↑in plasma concentrations of sildenafil Other Tolvaptan ↑in plasma concentrations of tolvaptan Contraindicated due to an increase in have been observed the plasma concentrations (see section 4.3). Mizolastine Potential ↑in plasma concentrations of Contraindicated due to the potential Halofantrine these drugs for serious cardiovascular events including QT prolongation (see section 4.3). Colchicine ↑in plasma concentrations of colchicine Not recommended due to a potential have been observed increase in colchicine-related toxicity. Contraindicated in patients with renal impairment (see section 4.3). Cinacalcet Cinacalcet Careful monitoring. AUC: ↑ 2 fold Dose adjustment of cinacalcet may Cmax: ↑ 2 fold be required. Ebastine ↑in plasma concentrations of ebastine Not recommended due to an have been observed increased risk in QT prolongation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ebastine (HOS-132877) halofantrine (HOS-085606) tolvaptan (HOS-109429) cinacalcet (HOS-128604) colchicine (HOS-086147) sildenafil (HOS-086162) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage f4b8a074be8cb33cde976bc82c1a4d3367f0b5bb387cf098f5830d9067354f34 · Zeichen 30001–31745 im Abschnitt